Código QR (código de barras bidimensional)

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

BackgroundThe oral, selective, and potent small molecule cyclin-dependent kinases (CDK) 4/6 inhibitor (CDK4/6i) abemaciclib has demonstrated efficacy in advanced breast cancer and high-risk early breast cancer. This Phase 1b study evaluated the safety, tolerability, pharmacokinetics, and antitumor a...

ver descrição completa

Na minha lista:
Principais autores: Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L. Puhalla, Alison Conlin, E. Claire Dees, Muralidhar Beeram, Sonya C. Chapman, Andrew Lithio, Lacey M. Litchfield, Matthew P. Goetz
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2025-03-01
coleção:Frontiers in Oncology
Assuntos:
abemaciclib
metastatic breast cancer
CDK4
CDK6
everolimus
exemestane
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2025.1555921/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados